|
|
Evaluation of oxytocin (OXT),endothelin-1 and nesfatin plasma concentrations in newly-diagnosed diabetic and non-diabetic patients with metabolic syndrome
|
|
|
|
|
نویسنده
|
abuhanoud a. ,kasabri v. ,bulayova n. ,akour a. ,bustanji h. ,khawaja n. ,hyasat d. ,silawi r. ,bustanji y. ,al-hiari y.
|
منبع
|
jordan journal of pharmaceutical sciences - 2016 - دوره : 9 - شماره : 3 - صفحه:163 -173
|
چکیده
|
Oxytocin (oxt) is implicated as a novel therapy of obesity-diabetes. nesfatin is an anorexigenic adipokine linked to improve insulin sensitivity and dysglycemia in obese/t2dm mice,while endothelin-1 (et-1) is an endothelium vasoconstrictor that is dysregulated in metabolic insulin resistance. the aim of this study was to investigate oxt,et- 1,and nesfatin plasma levels and the correlation between these biomarkers and the various metabolic parameters in the human. in a cross-sectional study,ms-subjects attended the national center for diabetes endocrinology and genetics were enrolled based on their blood glucose levels into (82 ms-non-diabetic vs. 89 ms-pre/diabetic patients). plasma oxt,et-1 and nesfatin levels were measured by competitive binding and sandwich enzyme-linked immunosorbent assays (elisa). when ms-pre/t2dm patients were compared to ms-controls,plasma oxt concentrations (pg/ml) were significantly lower (p < 0.001) (mean ± sd; 1206.28 ± 507.68 vs. 2224 ± 871.22); nesfatin plasma levels (ng/ml) were significantly higher (p < 0.01) (1.04 ± 2.20 vs. 0.31 ± 0.25); while no differences were observed in et-1 (pg/ml) plasma levels (p > 0.05) (4.21 ± 4.19 vs. 4.01 ± 3.51). in conclusion,the present study is the first one which demonstrates an increase in nesfatin concentrations in ms-pre/diabetic patients vs. ms-non-diabetic. our study reported a decrease in oxt levels in ms-pre/t2dm compared to ms-control. besides,et-1 concentrations had no significant difference between non-diabetic and diabetic-ms patients,serum oxt concentrations correlated with several clinical parameters; this is suggestive of oxt as a pharmacologic agent that opposes weight gain and improves insulin resistance. © 2016 dar publishers/the university of jordan. all rights reserved.
|
کلیدواژه
|
Endothelin-1 (ET-1); Enzyme-linked immunosorbent assay (ELISA); Metabolic syndrome (MS); Nesfatin; Oxytocin; Type 2 diabetes mellitus (T2DM)
|
آدرس
|
department faculty of pharmacy,the university of jordan,po box 11942,amman, Jordan, department faculty of pharmacy,the university of jordan,po box 11942,amman, Jordan, department faculty of pharmacy,the university of jordan,po box 11942,amman, Jordan, department faculty of pharmacy,the university of jordan,po box 11942,amman, Jordan, national center for diabetes,endocrinology and genetics,queen rania street,po box 13165,amman, Jordan, national center for diabetes,endocrinology and genetics,queen rania street,po box 13165,amman, Jordan, national center for diabetes,endocrinology and genetics,queen rania street,po box 13165,amman, Jordan, national center for diabetes,endocrinology and genetics,queen rania street,po box 13165,amman, Jordan, department faculty of pharmacy,the university of jordan,po box 11942,amman, Jordan, department faculty of pharmacy,the university of jordan,po box 11942,amman, Jordan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|